Radar›Companies›Top Health Services Stocks in USA
United States health services industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Top Health Services Stocks in USA

Five U.S.-listed health services names, read through one evidence stack: market path, official filing history, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderPrivia Health · 56
Strongest available pathInnovAge · -26.6%
Widest latest marginBLADE · 21.0%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1PRVA · Nasdaq

Privia Health

A U.S.-listed issuer classified by the SEC in Health Services

Founded 2016Pasadena, Texas$2.66B market cap
View full Companies Radar profile
56Moderate
Snapshot price$20.79as of page date
Monthly-close return-30.0%five-year window
FY2025 revenue$2.12BPrivia Health Group, Inc.
Net margin1.1%FY2025
P/E snapshot94.5xone ratio, not a verdict
Prism attention1.4%share across these five
Filing track recordRevenue, USD billions
+119.7%
$0$0.7B$1.4B$2.1BFY2021: $0.966BFY2022: $1.357BFY2023: $1.658BFY2024: $1.736BFY2025: $2.123B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 21.7%
52-week position14% through range
$19.53$28.82
News mentions531
Community mentions13partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal91/100
Management stability90/100
Market position7/100
Capital-event signal63/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2WGS · Nasdaq

Sema4

A U.S.-listed issuer classified by the SEC in Health Services

Founded 2012New York City, New York$2.57B market cap
View full Companies Radar profile
46Cautious
Snapshot price$86.33as of page date
Monthly-close return-71.5%five-year window
FY2025 revenue$0.43BGeneDx Holdings Corp.
Net margin-4.9%FY2025
P/E snapshot73.9xone ratio, not a verdict
Prism attention3.0%share across these five
Filing track recordRevenue, USD billions
+101.5%
$0$0.1B$0.3B$0.4BFY2021: $0.212BFY2022: $0.235BFY2023: $0.203BFY2024: $0.305BFY2025: $0.428B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 19.1%
52-week position39% through range
$32.21$170.9
News mentions1.1K
Community mentions31partial coverage
U.S.-scope patents6
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal57/100
Management stability90/100
Market position11/100
Capital-event signal56/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3INNV · Nasdaq

InnovAge

A U.S.-listed issuer classified by the SEC in Health Services

Founded 1990Denver, Colorado$1.47B market cap
View full Companies Radar profile
44Cautious
Snapshot price$10.86as of page date
Monthly-close return-26.6%five-year window
FY2025 revenue$0.85BInnovAge Holding Corp.
Net margin-3.6%FY2025
P/E snapshot26.5xone ratio, not a verdict
Prism attention0.9%share across these five
Filing track recordRevenue, USD billions
+33.9%
$0$0.3B$0.6B$0.9BFY2021: $0.638BFY2022: $0.699BFY2023: $0.688BFY2024: $0.764BFY2025: $0.854B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 7.6%
52-week position80% through range
$3.54$12.64
News mentions334
Community mentions19partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position4/100
Capital-event signal30/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 2 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4SRTA · Nasdaq

BLADE

A U.S.-listed issuer classified by the SEC in Health Services

Founded 2014New York City$528.1M market cap
View full Companies Radar profile
31Cautious
Snapshot price$5.97as of page date
Monthly-close return-27.5%five-year window
FY2025 revenue$0.20BStrata Critical Medical, Inc.
Net margin21.0%FY2025
Prism attention93.5%share across these five
Filing track recordRevenue, USD billions
+290.2%
$0$0.1B$0.2B$0.2BFY2021: $0.051BFY2022: $0.146BFY2023: $0.225BFY2024: $0.249BFY2025: $0.197B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 40.5%
52-week position80% through range
$3.85$6.50
News mentions34.4K
Community mentions0partial coverage
U.S.-scope patents953
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal57/100
Management stability70/100
Market position0/100
Capital-event signal0/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5DCGO · Nasdaq

Motion Acquisition

A U.S.-listed issuer classified by the SEC in Health Services

Founded 2015New York City, New York$39.3M market cap
View full Companies Radar profile
31Cautious
Snapshot price$0.40as of page date
Monthly-close return-95.8%five-year window
FY2025 revenue$0.32BDocGo Inc.
Net margin-56.6%FY2025
P/E snapshot2.8xone ratio, not a verdict
Prism attention1.2%share across these five
Filing track recordRevenue, USD billions
+1.1%
$0$0.1B$0.3B$0.4BFY2021: $0.319BFY2022: $0.441BFY2025: $0.322B202120222025
FY2021–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.5%
52-week position4% through range
$0.35$1.65
News mentions454
Community mentions1partial coverage
U.S.-scope patents98
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal44/100
Management stability70/100
Market position10/100
Capital-event signal15/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

InnovAge
-26.6%
BLADE
-27.5%
Privia Health
-30.0%
Sema4
-71.5%
Motion Acquisition
-95.8%

Latest revenue

USD billions, official filing scope shown on each company card.

Privia Health
$2.12B
InnovAge
$0.85B
Sema4
$0.43B
Motion Acquisition
$0.32B
BLADE
$0.20B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

BLADE
21.0%
Privia Health
1.1%
InnovAge
-3.6%
Sema4
-4.9%
Motion Acquisition
-56.6%

Prism news attention

Normalized share across these five names; attention is not quality.

BLADE
93.5%
Sema4
3.0%
Privia Health
1.4%
Motion Acquisition
1.2%
InnovAge
0.9%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized health services news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

BLADE leads the conversation

It holds 93.5% of measured health services news attention and also carries the basket's largest revenue base at $0.20B.

Price path

InnovAge leads the available price paths

Its monthly-close return is -26.6% for the five-year window. At the other end, Motion Acquisition is -95.8% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

BLADE has the widest latest margin

Its FY2025 net margin is 21.0%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Motion Acquisition shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 2.8x while its five-year window price return is -95.8%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · WGS

Sema4

1,119available Prism news records

Prism top themes

Price action & investor response
100
Earnings & financial performance
83
Leadership & governance
31
Capital allocation & transactions
26
Legal, arbitration & regulatory
22

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+0.0%199 latest 12m vs 199 prior 12m
2024-01: 8 mentions2024-02: 14 mentions2024-03: 4 mentions2024-04: 19 mentions2024-05: 9 mentions2024-06: 21 mentions2024-07: 14 mentions2024-08: 4 mentions2024-09: 10 mentions2024-10: 22 mentions2024-11: 17 mentions2024-12: 12 mentions2025-01: 13 mentions2025-02: 35 mentions2025-03: 24 mentions2025-04: 22 mentions2025-05: 10 mentions2025-06: 16 mentions2025-07: 8 mentions2025-08: 8 mentions2025-09: 9 mentions2025-10: 27 mentions2025-11: 8 mentions2025-12: 2 mentions2026-01: 19 mentions2026-02: 24 mentions2026-03: 26 mentions2026-04: 19 mentions2026-05: 38 mentions2026-06: 11 mentions2024-012026-06

Machine-classified coverage tone

86.8% positive-8.6 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 32gene therapy rare diseases 29stock performance 18rare disease clinical trials 15stock indices 14investment deal 14prenatal genetic testing 12stock surge 12

Keyword tag occurrences in available Prism news records.

Coverage: 2011-11-14–2026-06-18 · trend and themes shown through 2026-06
Areas of research · SRTA

BLADE

34,350available Prism news records

Prism top themes

Earnings & financial performance
136
Legal, arbitration & regulatory
76

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-27.6%3,546 latest 12m vs 4,898 prior 12m
2024-02: 309 mentions2024-03: 308 mentions2024-04: 256 mentions2024-05: 368 mentions2024-06: 318 mentions2024-07: 596 mentions2024-08: 528 mentions2024-09: 434 mentions2024-10: 442 mentions2024-11: 384 mentions2024-12: 310 mentions2025-01: 384 mentions2025-02: 399 mentions2025-03: 396 mentions2025-04: 487 mentions2025-05: 322 mentions2025-06: 311 mentions2025-07: 501 mentions2025-08: 455 mentions2025-09: 455 mentions2025-10: 301 mentions2025-11: 316 mentions2025-12: 301 mentions2026-01: 354 mentions2026-02: 285 mentions2026-03: 368 mentions2026-04: 448 mentions2026-05: 218 mentions2026-06: 35 mentions2026-07: 10 mentions2024-022026-07

Machine-classified coverage tone

82.2% positive-1.5 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

superhero franchise 785superhero 322marvel superhero 203gaming graphics notebook 190superhero comics 177gaming notebook 176high-performance laptop 176gaming gpu laptop 172

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-27 · trend and themes shown through 2026-07
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

WGS

Sema4

31 mentions
Products, pricing and logistics
17
Stock and valuation
5
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 31 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

PRVA

Privia Health

through 2026-02-26
Earnings releases 31Leadership changes 8M&A 3Listing / IPO 2
  1. Earnings releases

    Full-Year Performance For the Years Ended December 31, 2025: Total revenue $2,122.8 million, Net income $22.9 million.

  2. M&A

    Privia Health Group, Inc. (NASDAQ:PRVA) on Tuesday agreed to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH).

  3. Leadership changes

    Privia Health Group, Inc. announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

WGS

Sema4

through 2026-05-04
Leadership changes 10Funding Rounds 8M&A 8Earnings releases 4Business contracts 2
  1. Earnings releases

    Sema4 reported Q1 FY2026 revenue of $102.3M and net income of $-63.3M in the official-filing series.

  2. Earnings releases

    Sema4 reported FY2025 revenue of $427.5M and net income of $-21.0M in the official-filing series.

  3. Earnings releases

    Sema4 reported Q3 FY2025 revenue of $116.7M and net income of $-7.6M in the official-filing series.

Cached Prism company-event evidence fallback; totals describe available coverage and the displayed highlights prefer filing-backed earnings rows.

INNV

InnovAge

through 2026-02-05
Earnings releases 16Leadership changes 8Company announcements 1Lawsuits 1
  1. Earnings releases

    For the quarter ended Dec. 31, 2025, the company posted total revenue of $239.7 million, center-level contribution margin of $52.8 million, adjusted EBITDA of $22.2 million, and net income of $11.8 million.

  2. Leadership changes

    today announced the appointment of Sean Traynor to its Board of Directors (the “Board”), effective immediately.

  3. Company announcements

    InnovAge Holding Corp. proudly celebrates 35 years of empowering seniors to age independently in their homes and communities.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SRTA

BLADE

through 2026-05-06
Earnings releases 14
  1. Earnings releases

    BLADE reported Q1 FY2026 revenue of $67.4M and net income of $2.2M in the official-filing series.

  2. Earnings releases

    BLADE reported FY2025 revenue of $197.1M and net income of $41.3M in the official-filing series.

  3. Earnings releases

    BLADE reported Q3 FY2025 revenue of $49.3M in the official-filing series.

Cached Prism company-event evidence fallback; totals describe available coverage and the displayed highlights prefer filing-backed earnings rows.

DCGO

Motion Acquisition

through 2025-05-08
M&A 6Listing / IPO 2Earnings releases 1
  1. Earnings releases

    Motion Acquisition reported Q1 FY2025 revenue of $96.0M in the official-filing series.

Cached Prism company-event evidence fallback; totals describe available coverage and the displayed highlights prefer filing-backed earnings rows.

07 · Industry landscape

Health Services Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary health services news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

healthcare services market

10 sources50.0% extraction confidence
2024 extracted base$3.20T–$9.82T
2028 extracted forecast$6.26T–$9.82T
Implied source CAGR7.0%
aging populationtechnological advancementsincreasing use of telemedicine

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, United States, Nauru. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Health Services news pulse

294,667available Prism news records
Latest 12m volume+25.2%140915 vs 112542 records
Positive classified tone38.0%+3.7 pp vs prior four quarters
2024-01: 8,895 mentions2024-02: 7,909 mentions2024-03: 9,099 mentions2024-04: 7,256 mentions2024-05: 8,051 mentions2024-06: 7,350 mentions2024-07: 7,024 mentions2024-08: 6,303 mentions2024-09: 7,069 mentions2024-10: 8,338 mentions2024-11: 8,625 mentions2024-12: 8,452 mentions2025-01: 11,459 mentions2025-02: 13,197 mentions2025-03: 12,141 mentions2025-04: 12,267 mentions2025-05: 10,317 mentions2025-06: 6,761 mentions2025-07: 14,024 mentions2025-08: 40,026 mentions2025-09: 11,257 mentions2025-10: 9,140 mentions2025-11: 7,992 mentions2025-12: 7,843 mentions2026-01: 5,394 mentions2026-02: 10,998 mentions2026-03: 11,556 mentions2026-04: 14,407 mentions2026-05: 1,517 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching health, healthcare. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

political aspects of public health
26,141
public administration challenges
25,652
crisis management in governance
20,808
celebrity health and wellness updates
15,682
public health and safety regulations
13,413
government public health governance
10,419

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

public health funding 6,808public health orders vaccines 6,467vaccine policy controversies 6,426vaccine mandate legislation 5,873vaccine mandate compliance 5,754vaccine policy ethics 5,649vaccine decision-making 5,399anti-vaccination sentiment 5,119

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

aging population

10 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

political aspects of public health

26,141 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

17,815 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

rising healthcare costs

6,020 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+25.2% news volume

The latest 12 months contain 140,915 matched records versus 112,542 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

38.0% positive · +3.7pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five currently eligible U.S.-listed issuers classified under SEC SIC 8000 (Health Services). The builder rechecks price, filing and Prism evidence before assembling the basket. This is a focused research comparison, not a complete sector index.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Health Services Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

BLADE has the widest attention-readiness rank gap

It ranks #1 by measured news attention (93.5%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open BLADE in Companies Radar

BLADE shows a price-operating divergence to inspect

Its displayed filing-revenue change is +290.2% while its available monthly-close return is -27.5%. The signs differ, but the two measures cover different windows and do not establish causality.

Open BLADE in Companies Radar
Explanations

Attention measures coverage volume, not quality

BLADE's 93.5% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open BLADE in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Privia Health's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 56/100 score.

Open Privia Health in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon